Showing 17,841 - 17,860 results of 82,136 for search '(( a d decrease ) OR ( 50 ((((ms decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.05s Refine Results
  1. 17841
  2. 17842

    CDA deficiency leads to excess dCTP, inhibiting PARP-1 activity and leading to UFB formation. by Simon Gemble (168663)

    Published 2015
    “…(G) (1) CDA deficiency leads to intracellular dCTP accumulation, decreasing basal PARP-1 activity. (2) The decrease in basal PARP-1 activity leads to an increase in unreplicated DNA sequences (preferentially at centromeres and CFS sites). (3) During late G2/early mitosis, some of this unreplicated DNA is probably processed by MUS81-EME1 and ERCC1 nucleases as previously suggested [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1005384#pgen.1005384.ref036" target="_blank">36</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1005384#pgen.1005384.ref012" target="_blank">12</a>], leading to DNA synthesis during metaphase (EdU foci) and preventing supernumerary UFB formation. (4) Some of the excess unreplicated DNA sequences are not processed by the nucleases, leading to supernumerary UFB formation.…”
  3. 17843

    Immunocytochemistry showing localization of P53, P21, NF-κB p50, NF-κB p65 and MMP-9 in presence and absence of CY2 in HCT116 cells. by Sumit Kumar Dey (385318)

    Published 2013
    “…<p>DAPI was used for genomic DNA counterstaining (A) Translocation status of P53 and P21 in control cells (upper panel) and 20 µM CY2 treated cells (lower panel). …”
  4. 17844
  5. 17845
  6. 17846
  7. 17847
  8. 17848

    A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia by Aaron D. Schimmer (150194)

    Published 2014
    “…Obatoclax was increased to 45 mg/day (3 h×3 d) if ≤1 patient had a dose-limiting toxicity (DLT) and decreased to 20 mg/day (3 h×3 d) if DLT occurred in ≥2 patients. …”
  9. 17849

    Abnormal visual experience-induced homeostatic synaptic plasticity in GluR1-S831A mutants. by Anubhuti Goel (225953)

    Published 2011
    “…<p><b>(A)</b> Left: average mEPSC amplitude decreased with dark-exposure (D) and did not decrease any further with re-exposure to light (L). *: Significantly different from NR (N) at p<0.01, Fisher's PLSD posthoc test. …”
  10. 17850
  11. 17851
  12. 17852

    Effects of A1AR expression on response to hypoxia at E9.5 and E12.5. by Daniela L. Buscariollo (140729)

    Published 2013
    “…<p>A: At E9.5, responses to hypoxia in A1AR −/− (n = 15) and A1AR +/− (n = 50) embryos were studied. …”
  13. 17853

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    “…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”
  14. 17854

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    “…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”
  15. 17855

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    “…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”
  16. 17856

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    “…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”
  17. 17857

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    “…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”
  18. 17858

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    “…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”
  19. 17859

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    “…In the scenario analysis the profit margin contributed most to a higher CBPs for both drugs. Lower estimates resulted from assumed lower R&D costs.…”
  20. 17860